Hangzhou DAC Biotechnology
As of the edition of 20 October 2026, Hangzhou DAC Biotechnology runs 4 drugs.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Active | 4 |
| Total | 4 |
Where its trials are
- Cancer: 5 trials led
- Lungs and airways: 2 trials led
- Urinary and reproductive: 2 trials led